Classifying Alzheimer’s Disease Neuropathology Using Clinical and MRI Measurements

Author:

Zhuang Xiaowei123,Cordes Dietmar14,Bender Andrew R.1,Nandy Rajesh5,Oh Edwin C.236,Kinney Jefferson27,Caldwell Jessica Z.K.1,Cummings Jeffrey7,Miller Justin1

Affiliation:

1. Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

2. Interdisciplinary Neuroscience PhD Program, University of Nevada, Las Vegas, NV, USA

3. Laboratory of Neurogenetics and Precision Medicine, University of Nevada, Las Vegas, NV, USA

4. University of Colorado Boulder, Boulder, CO, USA

5. Department of Biostatistics and Epidemiology, School of Public Health, University of North Texas Health Science Center, Fort Worth, TX, USA

6. Department of Internal Medicine, School of Medicine, University of Nevada, Las Vegas, NV, USA

7. Department of Brain Health, Chambers-Grundy Center for Transformative Neuroscience, School of Integrated Health Sciences, University of Nevada, Las Vegas, NV, USA

Abstract

Background: Computer-aided machine learning models are being actively developed with clinically available biomarkers to diagnose Alzheimer’s disease (AD) in living persons. Despite considerable work with cross-sectional in vivo data, many models lack validation against postmortem AD neuropathological data. Objective: Train machine learning models to classify the presence or absence of autopsy-confirmed severe AD neuropathology using clinically available features. Methods: AD neuropathological status are assessed at postmortem for participants from the National Alzheimer’s Coordinating Center (NACC). Clinically available features are utilized, including demographics, Apolipoprotein E(APOE) genotype, and cortical thicknesses derived from ante-mortem MRI scans encompassing AD meta regions of interest (meta-ROI). Both logistic regression and random forest models are trained to identify linearly and nonlinearly separable features between participants with the presence (N = 91, age-at-MRI = 73.6±9.24, 38 women) or absence (N = 53, age-at-MRI = 68.93±19.69, 24 women) of severe AD neuropathology. The trained models are further validated in an external data set against in vivo amyloid biomarkers derived from PET imaging (amyloid-positive: N = 71, age-at-MRI = 74.17±6.37, 26 women; amyloid-negative: N = 73, age-at-MRI = 71.59±6.80, 41 women). Results: Our models achieve a cross-validation accuracy of 84.03% in classifying the presence or absence of severe AD neuropathology, and an external-validation accuracy of 70.14% in classifying in vivo amyloid positivity status. Conclusions: Our models show that clinically accessible features, including APOE genotype and cortical thinning encompassing AD meta-ROIs, are able to classify both postmortem confirmed AD neuropathological status and in vivo amyloid status with reasonable accuracies. These results suggest the potential utility of AD meta-ROIs in determining AD neuropathological status in living persons.

Publisher

IOS Press

Reference47 articles.

1. 2022 Alzheimer’s disease facts and figures. Alzheimers Dement 18, 700–789.

2. Lecanemab in early Alzheimer’s disease;van Dyck;N Engl J Med,2023

3. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease;Budd Haeberlein;J Prev Alzheimers Dis,2022

4. On the path to 2025: Understanding the Alzheimer’s disease continuum;Aisen;Alzheimers Res Ther,2017

5. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease;Jack;Alzheimers Dement,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3